Search

The article focuses on the FDA's review of Pfizer's drug, marstacimab, as a potential treatment for hemophilia A or B, aiming to prevent or reduce bleeding episodes, with a decision expected in the first quarter of 2024. Marstacimab targets the tissue factor pathway inhibitor and has demonstrated significant reductions in bleeding rates in phase 3 trials, potentially catering to patients with hemophilia A or B.

The article reports on the transmission of HIV and hepatitis C through the use of blood transfusions to hemophiliacs and the lack of information regarding possible risks in the 1970s and 1980s.

Focuses on blood clotting medicines contaminated with HIV as used by hemophiliacs in the United States. Class action lawsuit filed against four drug companies; HIV epidemic among the hemophilia community; Misinformation regarding infection risk.

Reports on the results of an Oxford Hemophilia Center study indicating that the increase in hemophiliacs' death rates in the 1990s is attributable to HIV infections. Death rate of hemophiliacs not infected with HIV; Hemophiliacs' inability to manufacture factor VIII in their blood.

Reveals that Canadian hemophiliac Mike McCarthy has launched a $1-billion class action lawsuit. How he believes that he and others got hepatitis C from tainted blood products made with blood collected in United States prisons; Who is named in the suit; States where the blood was collected; The compensation package that the Canadian federal and provincial governments have offered.